Company / Current Assets
Inhibikase Therapeutics, Inc. Current Assets History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$98.5M
FY2024
5-year range
$14.2M / $98.5M
FY2022-FY2024
Trend
+592.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets changed +593% YoY in FY2024, a notable deviation from the 2-year average annual change of +276%.
Based on SEC 10-K filings.
$98M in FY2024.
Improved from $24M to $98M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, current assets increased 592.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $98.5M | +592.8% |
| FY2023 | $14.2M | -41.7% |
| FY2022 | $24.4M | - |
| FY2021 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026